The story of Viagra and its parent , copyright, presents a tangled picture for cautious investors. While the iconic drug initially generated enormous revenues , its patent has lapsed , leading to competing versions flooding the arena. This erosion in cost presents a substantial challenge for copyright and any fund considering a heavy position in th